Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2006

01-12-2006 | Original

Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma

A single institution's experience

Authors: Faruk Tas, Sidika Kurul, Hakan Camlica, Erkan Topuz

Published in: Medical Oncology | Issue 4/2006

Login to get access
Metadata
Title
Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma
A single institution's experience
Authors
Faruk Tas
Sidika Kurul
Hakan Camlica
Erkan Topuz
Publication date
01-12-2006
Publisher
Humana Press
Published in
Medical Oncology / Issue 4/2006
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1385/MO:23:4:471

Other articles of this Issue 4/2006

Medical Oncology 4/2006 Go to the issue

Original Article

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

Original Article

Effect of diabetes mellitus on the epidemiology and outcomes of colon cancer

Original

Prevention of chemotherapy-induced neutropenia by special honey intake

Review

Bone diesease in multiple myeloma

Original Article

Small molecule antagonists of the TGF-β1/TGF-β receptor binding interaction

Original Article

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits